Compare EPSN & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EPSN | IXHL |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 134.7M |
| IPO Year | N/A | N/A |
| Metric | EPSN | IXHL |
|---|---|---|
| Price | $4.67 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 165.1K | ★ 7.3M |
| Earning Date | 03-18-2026 | 02-13-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | ★ 11.33 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $45,709,605.00 | $12,000.00 |
| Revenue This Year | $41.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.88 | ★ N/A |
| Revenue Growth | ★ 46.76 | N/A |
| 52 Week Low | $4.20 | $0.08 |
| 52 Week High | $8.50 | $2.25 |
| Indicator | EPSN | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 25.83 |
| Support Level | $4.64 | $0.30 |
| Resistance Level | $5.22 | $0.34 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 43.17 | 14.88 |
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.